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A B S T R A C T
Purpose: This study aimed to validate a Chinese version of the Morisky Medication Adherence Scale
(MMAS-8) in patients with epilepsy. The relationships between adherence, seizure frequency, and
adverse effects were assessed using this method.
Methods: Data from patients diagnosed with epilepsy at the Department of Neurology of Huashan
Hospital were collected between January and June 2013. To validate the MMAS-8, internal consistency,
test–retest reliability, and factor analysis were calculated. Relationships between adherence, seizure
frequency, and adverse effects were assessed using Pearson’s correlation.
Results: One hundred and eleven patients were recruited. The MMAS-8 had moderate internal
consistency (Cronbach’s a = 0.556) and good test–retest reliability (intraclass correlation coefﬁ-
cient = 0.729). The MMAS-8 adherence rate was 79.2%. MMAS-8 adherence was negatively correlated
with seizure frequency and adverse effects (r = –0.708, p < 0.001; r = –0.484, p < 0.001).
Conclusion: The MMAS-8 scale can be used as a tool to assess medication adherence in Chinese patients
with epilepsy. Better seizure control and lower rates of adverse effects were signiﬁcantly correlated with
higher adherence scores.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Epilepsy is a common neurological problem affecting approxi-
mately 65 million people globally.1 In China, the lifetime
prevalence of epilepsy is approximately nine million people
(7 per 1000), whereas currently six million people (4.6 per
1000) have active epilepsy.2
Antiepileptic drug (AED) regimens can dramatically control
seizure occurrence and improve the prognosis for patients with
epilepsy. However, it can be difﬁcult to achieve ideal efﬁcacy in
practice. One main reason for this is the non-adherence to AED
regimens. Cramer and colleagues have deﬁned adherence to ‘‘the
extent to which a patient acts in accordance with the prescribed
interval and dose of a dosing regimen.’’3 Non-adherence to AEDs
is common, with an average range from 30% to 60% and dose
omission of approximately 70%.4,5 Non-adherence to AEDs,
co-medications, seizure type, and factors such as gender and* Corresponding author. Department of Pharmacy, HuaShan Hospital, Fudan
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http://dx.doi.org/10.1016/j.seizure.2014.01.003co-morbidity6,7 may inﬂuence seizure risk. Furthermore, non-
adherence to AEDs may be associated with more serious outcomes
(increased hospitalization, inpatient days, and emergency depart-
ment visits) and increases in the cost of treatment.8,9 Thus, it is
important to assess medication adherence and discuss it with
patients when treatment appears to fail.10
Despite the lack of a gold standard for measuring adherence to
medication, both direct and indirect measures are currently used in
clinical practice. Direct methods, the most common measures of
adherence, involve monitoring metabolite concentration through
body ﬂuid (plasma and saliva) and therapeutic drug monitoring.
However, in clinical settings, it is often unreliable to measure
adherence through plasma concentration because a number of
factors can inﬂuence the results such as drug interaction and
physiological changes.11 In addition, assessing plasma concentra-
tion is expensive and time intensive. Thus, health care researchers
have begun developing indirect instruments (pill counts, medication
event monitoring systems [MEMS], and self-reporting),12,13 which
are non-invasive. Each of these has different advantages and
disadvantages.14 One self-reported questionnaire, the 8-item
Morisky Medication Adherence Scale (MMAS-8),15 is used to assess
adherence in outpatients with chronic disease. It is widely used
because it is free to administer, simple, and has a good relationships
with other measures of adherence.16 Because some studies havevier Ltd. All rights reserved.
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been validated in China, we were interested in translating the scale
and validating some of its psychometric properties in Chinese
patients with epilepsy. The utility of this scale in different languages
aids international studies,19 and it can meet the requirements of
non-English speaking people in China.
In addition, three main factors were revealed to be associated
with medication adherence: patient-related factors (e.g., beliefs
about AEDs),20 illness-related factors (e.g., seizure frequency),10,21
and medication-related factors (e.g., adverse effects).22 Currently,
studies have focused on assessing the relationship between
adherence and seizure frequency, suggesting patients experience
a lower seizure frequency when they are more adherent to their
AEDs.10,21 It is also important for health care providers to not only
understand how adherence is associated with seizure frequency,
but also potential factors related to adherence, such as adverse
effects. There have been a few studies conducted, and they found
that adherence is related to adverse effects.23 Because of the lack of
relevant research among Chinese patients with epilepsy, an
investigation of the relationships between adherence, seizure
frequency, and side effects is needed.
Therefore, the two main objectives in this study were: (a) to
validate a Chinese version of the MMAS-8 in patients with epilepsy
and (b) to evaluate the relationships between adherence, seizure
frequency, and adverse effects. In addition, the study hypothesized
MMAS-8 is moderately reliable in Chinese patients with epilepsy,
and adherence is negatively correlated with seizure frequency and
adverse effects. There have been: (a) studies validating MMAS-8
with moderate psychometric properties in patients with hyper-
tension,24 diabetes mellitus,25,26 osteoporosis,27 and those taking
warfarin28 and (b) two studies revealed that the relationship
between adherence and seizure frequency was negative.10,21
2. Methods
2.1. Study Design
This was a prospective, cross-sectional study. It was approved
by the Ethics Committee of Huashan Hospital (2013-006) before
data collection. Outpatients with epilepsy were recruited from
January to June 2013. To be eligible for participation, patients had
to: (a) be patients with epilepsy, (b) have been taking AEDs for at
least 3 months, and (c) provide written informed consent.
Patients with epilepsy were asked to complete a self-designed
questionnaire that contained three parts: history information form
(socio-demographic, age, education background, etc.; clinical:
etiology, age of onset of epilepsy, seizure frequency, etc.; and
medication data), the MMAS-8 scale, and the Liverpool Adverse
Event Proﬁle (LAEP). In addition, to assess the test-retest reliability
of the MMAS-8 scale, a random sample of 10% of the patients with
epilepsy was asked to complete the scale again 2-4 weeks later.
Finally, the relationships between adherence, seizure frequency,
and adverse effects were accessed by statistical methods.
2.2. Measures
2.2.1. MMAS-8
First, the scale was translated into Chinese by the author (see
Appendix A). To ensure consistency between the original and
translated versions, an expert clinician and an experienced clinical
pharmacist translated the initial translation back to English to
ensure that the content was the same (see Appendix B). The scale is
composed of eight items.15 Seven items (item 1 to item 7) are yes/
no questions, in which a ‘‘no’’ answer received a score of 1, and a
‘‘yes’’ answer received a score of 0, except for item 5, which was
reverse scored. Item 8 is measured on a ﬁve-point Likert scale.Responses of ‘‘never,’’ ‘‘once in a while,’’ ‘‘sometimes,’’ ‘‘usually,’’
and ‘‘all the time’’ were scored 1, 0.75, 0.50, 0.25, and 0,
respectively, whereas for item were scored ‘‘1’’ for ‘‘never’’ and
‘‘0’’ for other responses. The total scores ranged from 0 to 8. Scores
of 8, 6-8, and < 6 indicate high, medium, and low adherence,
respectively. Patients with scores of 8 and 6-8 were considered
adherent, and a score < 6 was considered as non-adherent in our
study.
2.2.2. LAEP
The adverse effects to AEDs were assessed using the Chinese
version of the LAEP.29 The LAEP is a validated 22-item question-
naire consisting of two factors: central nervous system (CNS) dose-
related (unsteadiness, tiredness, headache, double/blurred vision,
difﬁculty in concentration, shaky hands, dizziness, sleepiness,
memory problems and disturbed sleep), non-CNS dose-related and
psychiatric adverse effects (restlessness, feelings of aggression,
nervousness/agitation, hair loss, skin problems, upset stomach,
trouble with mouth, trouble with gums, weight gain, weight loss,
depression, and paresthesia).29 All items were scored using a four-
point Likert scale in which 1 = never, 2 = rarely, 3 = sometimes, and
4 = always. The scores for the LAEP range from 22 to 88, with higher
scores indicating greater adverse effects in these patients. Based on
a prior study,29 the mean score is 34.77 on the LEAP for Chinese
patients, and thus, patients with a score > 34.77 were considered
to be suffering severe adverse effects.
2.2.3. Seizure Frequency
The seizure frequency during the preceding month was self-
reported.
2.3. Statistical Analysis
Internal consistency reliability was assessed by calculating
the Cronbach’s a coefﬁcient. A Cronbach’s a  0.5 is considered
acceptable.26 To assess test-retest reliability, a random sample of
10% of the patients with epilepsy was readministered the MMAS-
8 after 2–4 weeks. Based on the results, we calculated an
intraclass correlation coefﬁcient (ICC). An ICC over 0.60 indicates
good test-retest reliability.30 Finally, factor analysis was con-
ducted to assess construct validity when the p value of Bartlett’s
test of sphericity was less than 0.001 and the value of Kaiser-
Meyer-Olkin measure of sampling adequacy (KMO) was more
than 0.5.31 Eigenvalues > 1 were used to assess the number of
factors, and items with loading on each 0.4 were viewed as the
corresponding factors.32
The relationships between MMAS-8 scores and continuous
variables were calculated using Pearson’s correlation, and associa-
tions with MMAS-8 scores and categorical variables were
examined by univariate analysis.
The signiﬁcance threshold was set as 0.05. Statistical analysis
was conducted by SPSS 16.0 for Windows.
3. Results
3.1. Patient and Clinical Data
A total of 111 patients with epilepsy were recruited for our
study (56 women and 55 men). The patients’ mean age (SD) was
32.9 (14.9) years. Approximately 91.9% were educated above the
elementary school (36.9% middle school, 21.6% high school, 32.4%
university, 0.9% Masters degree). The mean time (SD) since the ﬁrst
seizure was 22.3 (17.0) years. Around half of the patients (47.7%)
reported that they had less than one seizure in the previous month.
One type of AED (55.9%) was administered by patients, followed by
two types of AEDs (36.0%) and three types of AEDs (7.2%). The mean
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than 34.77, indicating patients more severe adverse effects than
those whose LAEP score were less than or equal to 34.77. All the
main socio-demographic and clinical characteristics are summa-
rized in Table 1.
3.2. MMAS-8 Adherence Measures
The mean MMAS-8 score was 6.64. The distribution of each
item is shown in Fig. 1. Of the total 111 patients, 32.4% (36) had
high adherence, 46.8% (52) had medium adherence, and 20.7% (23)
had low adherence. In total, 79.2% of the patients displayed some
adherence to their medication, and 20.7% patients did not display
much adherence. Signiﬁcant differences were not noted between
MMAS-8 scores and age (p = 0.209), time from ﬁrst seizure
(p = 0.394), duration of seizure (p = 0.680), educational level
(p = 0.566), gender (p = 0.098), type of seizure (p = 0.089), and
number of AEDs (p = 0.769).
3.3. Internal Consistency Reliability
The internal consistent reliability (Cronbach’s a) of the MMAS-
8 Chinese version was 0.556, indicating moderate reliability.
Cronbach’s a was slightly higher (0.649) when item 4 was
deleted.Table 1
Socio-demographic and clinical characteristics (N = 111).
Variables Number Association with
MMAS-8 scores
(p value)
Age (Mean, SD) 32 .9 (14.9) 0.209
Gender (N, %) 0.098
Male 55 (49.5%)
Female 56 (50.5%)
Education level (N, %) 0.566
No primary studies 2 (1.8%)
Primary studies 7 (6.3%)
Secondary studies 41 (36.9%)
Senior high studies 24 (21.6%) 0.089
University studies 36 (32.4%)
Master studies 1 (0.9%)
Seizure type (N, %)
SPS 5 (4.5%)
CPS 14 (12.6%)
SGTC 13 (11.7%)
SGTC + CPS 46 (41.4%) 0.394
GTCS 33 (29.7%) 0.680
Time from ﬁrst seizure
in years (mean, SD)
22.3 (17.0) 0.769
Time from seizure
in years (mean, SD)
10.6 (10.0)
Number of AEDs (N, %) 0.001*
One AED 62 (55.9%)
Two AEDs 40 (36.0%) 0.001*
Three AEDs 8 (7.2%)
Four AEDs 1 (0.9%)
Seizure frequencyy (N, %)
0 53 (47.7%)
>1 58 (52.3%)
LAEP scores z(N, %)
>34.77 24 (21.6%)
34.77 87 (78.4%)
SPS, simple partial seizure; CPS, complex partial seizure; SGTC, secondarily
generalized tonic-clonic seizure; GTCS, generalized tonic-clonic seizure; AEDs,
antiepileptic drugs; SD, standard deviation; MMAS, Morisky Medication Adherence
Scale; LAEP, Liverpool Adverse Events Proﬁle.
ySeizure frequency during the preceding month.
zThe mean scores were 34.77 in LAEP for Chinese patients in a prior study, and those
patients with a score >34.77 were considered to have suffered more severe adverse
effects than patients with a score 34.77.
*p < 0.001.3.4. Test-Retest Reliability
A total of 11 patients were asked to recomplete the scale 2-4
weeks later. The mean score of adherence was 7.41. A total of 9.1%
(1 of 11), 27.3% (3 of 11), and 63.6% (7 of 11) patients reported low,
medium, and high adherence, respectively. According to our
criterion, 90.9% (10 of 11) of patients were considered as adherent,
and 9.1% (1 of 11) of patients were viewed as non-adherent.
The ICC of the Chinese MMAS-8 was 0.729, indicating good
reproducibility.
3.5. Construct Validity
Bartlett’s test of sphericity (p < 0.001) and the Kaiser-Meyer-
Olkin (p = 0.694) test were performed, which indicated that the
Chinese MMAS-8 was suitable for factor analysis. Three factors
(eigenvalue > 1) were extracted in our study, explaining a total
variance of 58.2%. The factor loadings for each item are illustrated
in Table 2. Factor 1 had an eigenvalue of 2.440, accounted for
30.495% of the variance and comprised items 1, 2, 3, 6, 7, and 8.
Factor 2 had an eigenvalue of 1.139, explained 14.239% of the
variance and comprised items 3 and 6. Factor 3 had an eigenvalue
of 1.074, explained 13.421% of the variance and comprised items 5
and 6.
3.6. Relationship between Adherence, Seizure Frequency, and Adverse
Effects
There was a signiﬁcant correlation found between adherence
and seizure frequency (r = 0.708, p < 0.001), adherence and
adverse effects (r = 0.484, p < 0.001). Also, adherence was
associated with CNS (r = 0.453, p < 0.001) and non-CNS
(r = 0.362, p < 0.001) factors. To take into account the inﬂuence
of adverse effects, we assessed the relationship between adherence
and seizure frequency, using partial analysis. Adherence was also
signiﬁcantly associated with seizure frequency (r = 0.166,
p < 0.001) after controlling for the inﬂuence of adverse effects.
4. Discussion
The main objective of our study was to validate the MMAS-8 in
epilepsy patients in China. To the best of our knowledge, this is also
the ﬁrst study to validate this scale in Chinese patients. Several
validation studies focused on different languages for this scale
have been conducted.24–28 Korb-Savoldelli et al.24 validated the
French version of this scale in patients with hypertension, and the
Cronbach’s a was 0.54. Lee et al.25 and Harith et al.26 validated the
version Korean and Malaysian version in patients with type 2
diabetes, and the Cronbach’s a scores were 0.66 and 0.675,
respectively. Wang et al.28 validated the Singaporean version in
patients who taken warfarin, with a Cronbach’s a of 0.56. These
previous studies validating the MMAS-8 indicate this scale was
moderately reliable, and similar results were found in our study:
moderate reliability (Cronbach’s a = 0.556) and good test-retest
reliability (ICC = 0.729). These results might be explained by: (a)
the small number of participants involved into our study, as the
number size would inﬂuence the internal consistency 33 and (b)
this scale is composed of seven yes/no questions and one ﬁve-point
Likert scale, and yes/no questions can lower the value of
Cronbach’s a because of higher measurement error.34 Even though
a Cronbach’s a  0.8 is recommended, a Cronbach’s a  0.5 is
considered acceptable according to Bowling and Robinson
et al.35,36 The Cronbach’s a for the Chinese MMAS-8 was 0.556,
which was viewed as acceptable. Accordingly, this indicates the
Chinese MMAS-8 has potential as a tool to help in assessing
medication adherence in epileptic patients.
Fig. 1. Distribution of each item of Morisky Medication Adherence Scale.
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participants, 32.4%, 46.8%, and 20.7% displayed high, medium,
and low adherence, respectively, with 79.2% displaying some
adherence, and 20.7% displayed no adherence. These results are
consistent with those of a previous study that used the four-item
MMAS, which reported a total adherence of approximately 74.8%
(high adherence and medium adherence) in Chinese patients with
epilepsy.22 Similarly, Avani et al. reported a total adherence of
approximately 79.4% in patients with new-onset epilepsy, using
MEMS TrackCap which is viewed as a more accurate measure than
others.37
In this context, the Chinese version of the MMAS-8 can be used
as a tool to evaluate medication adherence, as well as to capture
the non-adherence among Chinese patients with epilepsy. This is
the ﬁrst study in China to assess the relationships between
adherence, seizure frequency, and adverse effects using the
MMAS-8. As we expected, the ﬁndings of our study, including
the negative relation between adherence and seizure frequency
and adherence and adverse effects, resulting in lower seizure
frequency and adverse effects, were associated with higher
adherence. Similar results regarding the relationship between
adherence and seizure frequency were found by Jones et al. and
Collin et al.10,21 Collin and his colleagues demonstrated that non-
adherence was associated with reduced seizure control.21 Another
study in the UK demonstrated a negative correlation between
adherence and seizure frequency even though there was no
signiﬁcant difference.10 With respect to the relationship between
adherence and adverse effects, the results in our study are not
consistent with another published study which demonstrated that
a signiﬁcant difference was not found among patients with
different levels of adherence.23 The discrepancy might be
explained by the fact that a different scale was used for assessing
adverse effects. Compared with the scale only containing ﬁve itemsTable 2
Factorial loading on the eight-item Morisky Medication Adherence Scale.
Factor
1 2 3
Item 1 0.685* 0.352 0.213
Item 2 0.678* 0.353 0.069
Item 3 0.629* 0.474* 0.331
Item 4 0.258 0.396 0.249
Item 5 0.031 0.535 0.615*
Item 6 0.552* 0.471* 0.483*
Item 7 0.604* 0.017 0.309
Item 8 0.614* 0.032 0.382
Eigenvalue 2.440 1.139 1.074
Explained variance (58.2%) 30.495% 14.239% 13.421%
*Indicates items loading  0.4.used by Sweileh et al.,23 the LAEP scale we used contains 22 items
and covers both systemic and neurological problems.38 In addition,
the validity and reliability of this scale has been assessed in
Chinese patients with epilepsy. These results indicate that
assessing adherence with the Morisky scale may be able to predict
the seizure frequency and side effects in clinical settings, which,
consequently, would result in better management of epilepsy
in China.
Despite the important implications of our ﬁndings, our study
has several limitations. (a) This was a cross-sectional study rather
than a randomized clinical trial. Thus, it can only illustrate the
adherence rate for a certain period of time, which is problematic
because adherence rates have been demonstrated to change with
time.37,39,40 (b) Patients with epilepsy experience some physical
disorders similar to adverse effects, making it difﬁcult to
distinguish whether the cause of the symptoms is either the drug
or seizures. To avoid this bias, we reminded the patients that the
questionnaire items were mainly evaluating drug behavior and not
seizures. (c) The accuracy of the self-reported seizure frequency is
a concern because the frequency was likely under-reported
because of a lack of cognition of the clinical manifestation or
the lack of a witness at the time the seizure occurred.41 Even
though EEG monitoring is a vital tool to capture seizure occurrence,
continuous EEG monitoring is impractical for outpatients. As a
result, many studies use self-reporting.20,21 In our study, the
seizure frequency was mostly extracted from self-reported diaries,
and these data may be subject to incorrect reporting.
5. Conclusion
The Chinese version of the MMAS-8 is a simple, free to
administer, and convenient measurement of medication adher-
ence in patients with epilepsy. In addition, it was demonstrated to
have acceptable reliability and validity. Using this scale, the
relationships between adherence, seizure frequency, and adverse
effects were revealed in our study. Our results indicate that better
seizure control and lower adverse effects were signiﬁcantly
correlated with higher adherence scores.
As we mentioned earlier, almost all validated MMAS-8 versions
in different languages have displayed moderate reliability.
Therefore, further studies are needed to investigate the reliability
and validity of this scale in different clinical settings and different
populations.
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